Discrete Event Simulation Model for Cost-Effectiveness Evaluation of Screening for Asymptomatic Patients with Lower Extremity Arterial Disease

Lower limb ischemic disease (LEAD) affects a significant portion of the population, with most patients being asymptomatic. Patient screening is necessary because LEAD patients have an increased risk of occurrence of other cardiovascular events and manifestations of disease, in terms of leg symptoms such as intermittent claudication, critical limb ischemia, or amputation. The aim of this work was to evaluate the cost-effectiveness of screening using ABI diagnostics in asymptomatic patients and its impact on limb symptoms associated with LEAD. A discrete event simulation model was created to capture lifetime costs and effects. Costs were calculated from the perspective of the health care payer, and the effects were calculated as QALYs. A cost-effectiveness analysis was performed to compare ABI screening examination and the situation without such screening. A probabilistic sensitivity analysis and scenario analysis were carried out to evaluate the robustness of the results. In the basic setting, the screening intervention was a more expensive intervention, at a cost of CZK 174,010, compared to CZK 70,177 for the strategy without screening. The benefits of screening were estimated at 14.73 QALYs, with 14.46 QALYs without screening. The final ICER value of CZK 389,738 per QALY is below the willingness to pay threshold. Likewise, the results of the probabilistic sensitivity analysis and of the scenario analysis were below the threshold of willingness to pay, thus confirming the robustness of the results. In conclusion, ABI screening appears to be a cost-effective strategy for asymptomatic patients aged 50 years when compared to the no-screening option

Arterial disease · Asymptomatic · Cost effectiveness · Cost-effectiveness analysis · Disease · Economic evaluation · Environmental health · Intermittent claudication · Pathology · Physical therapy · Population · Quality-adjusted life year · Vascular disease · Diagnosis and Treatment of Venous Diseases · Health Systems, Economic Evaluations, Quality of Life · Medicine · Peripheral Artery Disease Management · Emergency Medicine · Internal Medicine · Surgery

• Cost-effectiveness of diagnostic imaging modalities in symptomatic patients with lower limb peripheral arterial disease

  Open Access•Vojtěch Kamenský, Vladimír Rogalewicz et al.•Frontiers in Public Health•2024

  Add to list

• Burden of HPV-induced diseases and cost effectiveness of catch-up vaccination in Czech Republic

  Open Access•Vojtěch Kamenský, Lukáš Dostálek et al.•BMC Public Health•2025

  Add to list

• Screen or not to screen for peripheral arterial disease

  Open Access•Anil Vaidya, Manuela A Joore et al.•BMC Public Health•2014

  Add to list